Non-steroid agents for idiopathic pulmonary fibrosis.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2010-09-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD003134.pub2PMID 20824834
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transbronchial biopsy via flexible fiberoptic bronchoscope; results in 164 patients.

  2015cited by this paper
• BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.

  2011cited by this paper
• Strategies for treating idiopathic pulmonary fibrosis

  2010cited by this paper
• [Comparative study between oral azathioprine and intravenous cyclophosphamide pulses in the treatment of idiopathic pulmonary fibrosis].

  2010cited by this paper
• Comparative Study of Oral Azathioprine and Intravenous Cyclophosphamide Pulses in the Treatment of Idiopathic Pulmonary Fibrosis

  2010cited by this paper
• Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.

  2010cited by this paper
• The STEP-IPF Trial: Sildenafil Trial Of Exercise Performance In Idiopathic Pulmonary Fibrosis

  2010cited by this paper
• The CAPACITY (CAP) Trials: Randomized, Double-Blind, Placebo-Controlled, Phase III Trials of Pirfenidone (PFD) in Patients with Idiopathic Pulmonary Fibrosis (IPF).

  2009cited by this paper
• Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.

  2009cited by this paper
• Emerging concepts in the pathogenesis of lung fibrosis.

  2009cited by this paper
• Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial

  2009cited by this paper
• Predictors of Mortality in Patients with Idiopathic Pulmonary Fibrosis (IPF).

  2009cited by this paper
• Pirfenidone in idiopathic pulmonary fibrosis

  2009cited by this paper
• Epidemiology of interstitial lung diseases in Greece.

  2009cited by this paper
• MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis

  2008cited by this paper
• Fleischner Society: glossary of terms for thoracic imaging.

  2008cited by this paper
• Interstitial lung disease guideline

  2008cited by this paper
• Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

  2008cited by this paper
• Animal models of pulmonary fibrosis: how far from effective reality?

  2008cited by this paper
• The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

  2008cited by this paper
• BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.

  2008cited by this paper
• Acute exacerbations of idiopathic pulmonary fibrosis.

  2007cited by this paper
• Early interstitial lung disease in familial pulmonary fibrosis.

  2007cited by this paper
• Acute Exacerbation (Acute Lung Injury of Unknown Cause) in UIP and Other Forms of Fibrotic Interstitial Pneumonias

  2007cited by this paper
• Is idiopathic pulmonary fibrosis an environmental disease?

  2006cited by this paper
• Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis

  2006cited by this paper
• Survival in idiopathic pulmonary fibrosis-cytotoxic agents compared to corticosteroids.

  2006cited by this paper
• High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis

  2006cited by this paper
• Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features

  2006cited by this paper
• Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK

  2006cited by this paper
• Histologic spectrum of idiopathic interstitial pneumonias.

  2006cited by this paper
• Incidence and prevalence of idiopathic pulmonary fibrosis.

  2006cited by this paper
• Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan.

  2005cited by this paper
• Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

  2005cited by this paper
• Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia

  2005cited by this paper
• High-dose acetylcysteine in idiopathic pulmonary fibrosis.

  2005cited by this paper
• The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis

  2005cited by this paper
• Anticoagulant therapy for idiopathic pulmonary fibrosis.

  2005cited by this paper
• Major histocompatibility complex and alveolar epithelial apoptosis in idiopathic pulmonary fibrosis

  2005cited by this paper
• Clinical and pathologic features of familial interstitial pneumonia.

  2005cited by this paper
• Familial idiopathic pulmonary fibrosis: clinical features and outcome.

  2005cited by this paper
• Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

  2005cited by this paper
• Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis.

  2004cited by this paper
• Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.

  2004cited by this paper
• A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.

  2004cited by this paper
• Immunomodulatory agents for idiopathic pulmonary fibrosis.

  2003cited by this paper
• Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.

  2003cited by this paper
• Corticosteroids for idiopathic pulmonary fibrosis.

  2003cited by this paper
• Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis.

  2003cited by this paper
• Usefulness of serum KL-6 for early diagnosis of idiopathic pulmonary fibrosis in patients with hepatitis C virus.

  2003cited by this paper
• American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors

  2002cited by this paper
• Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans

  2002cited by this paper
• A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis.

  2002cited by this paper
• Is it necessary to treat all patients with idiopathic pulmonary fibrosis?

  2001cited by this paper
• Systematic reviews in health care: Assessing the quality of controlled clinical trials.

  2001cited by this paper
• Idiopathic Pulmonary Fibrosis: Survival as a Function of Oxygen Therapy and Treatment Program

  2001cited by this paper
• Epstein-Barr virus and wild p53 in idiopathic pulmonary fibrosis.

  2001cited by this paper
• Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis.

  2001cited by this paper
• Risk of cryptogenic fibrosing alveolitis in metal workers.

  2000cited by this paper
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

  2000cited by this paper
• Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis.

  2000cited by this paper
• Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement

  2000cited by this paper
• Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids.

  2000cited by this paper
• Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival.

  2000cited by this paper
• Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study.

  1999cited by this paper
• The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study.

  1999cited by this paper
• Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients.

  1999cited by this paper
• A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis.

  1999cited by this paper
• The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis.

  1999cited by this paper
• Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent , Pirfenidone Results of a Prospective , Open-label Phase II Study

  1999cited by this paper
• Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis.

  1998cited by this paper
• [Treatment of idiopathic pulmonary fibrosis with colchicine].

  1998cited by this paper
• Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages.

  1998cited by this paper
• Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis.

  1998cited by this paper
• Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group.

  1998cited by this paper
• Clinical Investigations: Idiopathic DiseaseColchicine, D-Penicillamine, and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: A Controlled Clinical Trial

  1998cited by this paper
• Clinical Investigations: BAC, UIP, SODSurvival in Patients With Cryptogenic Fibrosing Alveolitis: A Population-Based Cohort Study

  1998cited by this paper
• Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

  1998cited by this paper
• Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

  1998cited by this paper
• Viruses and idiopathic pulmonary fibrosis.

  1997cited by this paper
• Viruses and idiopathic pulmonary fibrosis.

  1997cited by this paper
• Colchicine versus prednisone as treatment of usual interstitial pneumonia.

  1997cited by this paper
• Cryptogenic fibrosing alveolitis.

  1997cited by this paper
• Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression.

  1997cited by this paper
• Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis.

  1996cited by this paper
• Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis.

  1996cited by this paper
• Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals.

  1995cited by this paper
• Oxidants/antioxidants in idiopathic pulmonary fibrosis.

  1995cited by this paper
• Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.

  1995cited by this paper
• The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis.

  1994cited by this paper
• Determinants of progression in idiopathic pulmonary fibrosis.

  1994cited by this paper
• Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure.

  1994cited by this paper
• The epidemiology of interstitial lung diseases.

  1994cited by this paper
• Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis.

  1994cited by this paper
• Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases.

  1993cited by this paper
• Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies.

  1993cited by this paper
• Efficacy of cyclosporine to reduce steroids in patients with idiopathic pulmonary fibrosis before lung transplantation.

  1993cited by this paper
• Colchicine in the treatment of pulmonary fibrosis.

  1993cited by this paper
• Fibroblast chemotactic response elicited by native bronchoalveolar lavage fluid from patients with fibrosing alveolitis.

  1993cited by this paper
• Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis.

  1992cited by this paper

• Optimising pirfenidone dosage regimens in idiopathic pulmonary fibrosis: towards a guide for personalised treatment

  2025cites this paper
• Pirfenidone Mitigates TGF-β-induced Inflammation Following Virus Infection.

  2025cites this paper
• The Effect of Sodium Pyruvate Nasal Spray on Coughing in Patients with Idiopathic Pulmonary Fibrosis: A Double-Blinded Randomized Placebo-Controlled Phase 3 Clinical Trial

  2024cites this paper
• Pulmonary Fibrosis: Unveiling the Pathogenesis, Exploring Therapeutic Targets, and Advancements in Drug Delivery Strategies

  2023cites this paper
• β-Carboline Alkaloids From the Deep-Sea Fungus Trichoderma sp. MCCC 3A01244 as a New Type of Anti-pulmonary Fibrosis Agent That Inhibits TGF-β/Smad Signaling Pathway

  2022cites this paper
• Diagnosis and management of idiopathic pulmonary fibrosis

  2022cites this paper
• Selective Inhibition of Bromodomain-Containing Protein 4 Reduces Myofibroblast Transdifferentiation and Pulmonary Fibrosis

  2022cites this paper
• [French practical guidelines for the diagnosis and management of IPF - 2021 update, full version].

  2022cites this paper
• French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2021 update. Full-length version.

  2022cites this paper
• Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2

  2022cites this paper
• Colchicine-new horizons for an ancient drug.

  2021cites this paper
• [Desensitization to pirfenidone. Report of one case].

  2021cites this paper
• Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic pulmonary fibrosis.

  2020cites this paper
• Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology

  2020cites this paper
• Differences in right ventricular dysfunction in patients with idiopathic pulmonary hypertension versus secondary pulmonary hypertension.

  2020cites this paper
• Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis

  2020cites this paper
• Inhalation: A means to explore and optimize nintedanib’s pharmacokinetic/pharmacodynamic relationship

  2020cites this paper
• Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis

  2019cites this paper
• IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis

  2019cites this paper
• Idiopathic Pulmonary Fibrosis

  2019cites this paper
• Tratamiento farmacológico en la fibrosis pulmonar idiopática. Drogas modificadoras de enfermedad

  2019cites this paper
• Pharmacologic Treatment of IPF

  2018cites this paper
• Idiopathic pulmonary fibrosis: pathogenesis and management

  2018cites this paper
• Shared and distinct genetic determinants between idiopathic pulmonary fibrosis and other pulmonary traits

  2018cites this paper
• The disturbed redox‐balance in pulmonary fibrosis is modulated by the plant flavonoid quercetin

  2017cites this paper
• Is nintedanib effective for idiopathic pulmonary fibrosis?

  2017cites this paper
• Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?

  2017cites this paper
• Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial

  2017cites this paper
• Is pirfenidone effective for idiopathic pulmonary fibrosis?

  2017cites this paper
• Interstitial Lung Disease, Body Mass Index, Energy Expenditure and Malnutrition—a Review

  2017cites this paper
• French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update. Short-length version.

  2017cites this paper
• OFIL VOL 27-1-2017_MaquetaciÛn 1

  2017cites this paper
• [French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. 2017 update. Full-length update].

  2017cites this paper
• Chronic Lower Respiratory Tract Diseases

  2017cites this paper
• French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update. Full-length version.

  2017cites this paper
• Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis

  2017cites this paper
• Predictive factors for the effect of pirfenidone in idiopathic pulmonary fibrosis

  2017cites this paper
• Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain – results of a Delphi Panel

  2016cites this paper
• Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis

  2016cites this paper
• Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results

  2016cites this paper
• Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report

  2016cites this paper
• Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

  2016cites this paper
• Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.

  2016cites this paper
• Clinical approach to gastro-oesophageal reflux in idiopathic pulmonary fibrosis

  2016cites this paper
• Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy

  2016cites this paper
• Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis.

  2016cites this paper
• Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.

  2016cites this paper
• Pirfenidone in Lung Interstitial Diseases: Indications and How to Evaluate its Effects

  2016cites this paper
• New perspectives on management of idiopathic pulmonary fibrosis

  2016cites this paper
• Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.

  2016cites this paper
• All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.

  2015cites this paper
• Idiopathic pulmonary fibrosis: An update

  2015cites this paper
• [Programs for Continuing Medical Education: B session; 3. Diagnosis and therapy of interstitial pneumonias--Up to date].

  2015cites this paper
• Novel treatments for idiopathic pulmonary fibrosis.

  2015cites this paper
• Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.

  2015cites this paper
• Pharmacological treatment of idiopathic pulmonary fibrosis: an update.

  2015cites this paper
• Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience

  2015cites this paper
• Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future

  2015cites this paper
• Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.

  2015cites this paper
• A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.

  2015cites this paper
• Tratamiento de la fibrosis pulmonar idiopática: de la teoría a la vida real

  2015cites this paper
• Update on therapeutic management of idiopathic pulmonary fibrosis

  2015cites this paper
• Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience

  2015cites this paper
• The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation.

  2015cites this paper
• Pirfenidone: an orphan drug for treating idiopathic pulmonary fibrosis

  2015influential citation
• Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis

  2015cites this paper
• Idiopathic Pulmonary Fibrosis: Treatment and Prognosis

  2015cites this paper
• The Core Evidence

  2015cites this paper
• Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis

  2015cites this paper
• Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives

  2015cites this paper
• Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences

  2015cites this paper
• The Challenges of Clinical Research in Orphan Diseases

  2015cites this paper
• Antifibrotische Therapien

  2014cites this paper
• Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis

  2014cites this paper
• Nintedanib: A Novel Therapeutic Approach for Idiopathic Pulmonary Fibrosis

  2014cites this paper
• Pirfenidone: an update on clinical trial data and insights from everyday practice

  2014cites this paper
• Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications

  2014cites this paper
• Novel approaches to pulmonary fibrosis.

  2014cites this paper
• The treatment of idiopathic pulmonary fibrosis

  2014cites this paper
• Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis

  2014cites this paper
• Pirfenidone for the treatment of idiopathic pulmonary fibrosis

  2014cites this paper
• Pirfenidone for the treatment of idiopathic pulmonary fibrosis

  2014cites this paper
• Idiopathic pulmonary fibrosis: early detection and referral.

  2014cites this paper
• Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis

  2014cites this paper
• Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-Life Experience from a German Tertiary Referral Center for Interstitial Lung Diseases

  2014cites this paper
• Slowing progression of idiopathic pulmonary fibrosis with pirfenidone: from clinical trials to real-life experience

  2014cites this paper
• Pharmacological Treatment of Idiopathic Pulmonary Fibrosis

  2014cites this paper
• Interstitial lung diseases (ILD): Simplified, advances, what's new

  2014cites this paper
• Current and Emerging Treatment Options in Interstitial Lung Disease

  2014cites this paper
• Pirfenidone for the treatment of idiopathic pulmonary

  2014cites this paper
• Ultrastructural and functional characterization of myofibroblasts in lung diseases

  2014cites this paper
• Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis

  2014cites this paper
• Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis

  2014cites this paper
• Interstitial lung disease

  2013cites this paper
• Therapie der idiopathischen Lungenfibrose

  2013cites this paper
• Review of idiopathic pulmonary fibrosis diagnosis and management recommendations in Europe

  2013cites this paper
• 84 – Clinical Features and Treatment of Scleroderma

  2013cites this paper
• New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research

  2013cites this paper
• Die deutsche IPF-Leitlinie: national vs. international

  2013cites this paper
• Idiopaatiline kopsufibroos – äsjane kannapööre ravistrateegias uute lootuste nimel

  2013cites this paper